

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
CIN: L24230GJ1993PLC019050



**Date: February 10, 2021**

**National Stock Exchange of India Limited,**  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051  
**NSE Code: SUNPHARMA**

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers, Dalal Street,  
Mumbai - 400 001  
**BSE Code: 524715**

Dear Sir/Madam,

**Sub: Submission of copies of Newspaper Advertisement regarding Notice of the National Company Law Tribunal (“NCLT”) Convened Meetings of the Sun Pharmaceutical Industries Limited (“the Company”)**

In terms of Rule 7 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 read with any other applicable provisions of the Companies Act, 2013, please find enclosed herewith the copies of the newspaper advertisements by the Company in English Daily ‘Financial Express’, Ahmedabad edition (although it appeared in All India Editions) and Gujarati translation of the same in Gujarati daily ‘Financial Express’ Ahmedabad edition dated 10th February, 2021, in accordance with the statutory requirements and as directed by Hon’ble National Company Law Tribunal, Ahmedabad Bench, vide its order dated January 7, 2021, regarding convening the NCLT Convened Meetings of the equity shareholders and unsecured creditors of the Company on Tuesday, March 16, 2021 at 3.15 p.m. IST and 2.00 p.m. IST respectively, for the purpose of considering and if thought fit, to approve the Scheme of Amalgamation and merger of Sun Pharma Global FZE ("Transferor Company") with Sun Pharmaceutical Industries Limited ("Transferee Company") and their respective members and creditors ("Scheme of Amalgamation") for the merger of Transferor Company with Transferee Company.

This is for your information and dissemination.

Thanking You,

**For Sun Pharmaceutical Industries Limited**

Ashok  
Indulal  
Bhuta

Digitally signed  
by Ashok Indulal  
Bhuta  
Date: 2021.02.10  
15:27:03+05'30'

**Ashok I. Bhuta**

**Sr. GM – Secretarial &  
Compliance Officer**

Enclosures: as above

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

(CIN: L17123GJ2015PLC083569)
Registered Office: Aerodrome Road, Jamnagar 361 006 (Gujarat)
e-mail: cosec@digjam.co.in, Tel.: +91-288-2712972-3

EXTRACTS OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

Table with 4 columns: Particulars, Quarter ended 31.12.2020, 9 Months ended 31.12.2020, Quarter ended 31.12.2019. Rows include Total Income from Operations, Net (Loss) for the period, Earnings per Share, etc.

Note: 1. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For DIGJAM LIMITED
Ajay Agarwal
Whole-Time Director
Place: Mumbai
Date: February 8, 2021

SUN PHARMACEUTICAL INDUSTRIES LIMITED
Registered Office: SPARC, Tandlaja, Vadodara - 390 012, Gujarat, India.
Corporate Office: Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon-East, Mumbai - 400 063, India.

BEFORE THE NATIONAL COMPANY LAW TRIBUNAL AHMEDABAD BENCH
CA(CAA) NO. 90/NCLT/AHM/2020

In the matter of Sections 230 to 232 read with Section 234 and other applicable provisions of the Companies Act, 2013; AND
In the matter of Scheme of Amalgamation and Merger of Sun Pharma Global FZE with Sun Pharmaceutical Industries Limited, and their respective members and creditors.

Sun Pharmaceutical Industries Limited (CIN: L24230GJ1993PLC019050), a company registered under the provisions of Companies Act, 1956 and having its Registered Office at SPARC, Tandlaja, Vadodara-390 012, in the State of Gujarat.

NOTICE AND ADVERTISEMENT OF MEETINGS OF EQUITY SHAREHOLDERS AND UNSECURED CREDITORS OF THE APPLICANT/TRANSFEREE COMPANY

NOTICE is hereby given that the Hon'ble National Company Law Tribunal, Ahmedabad Bench ("NCLT") by an order dated January 7, 2021 ("NCLT Order") has directed separate meetings of the equity shareholders and unsecured creditors of the Applicant Company for the purpose of considering and if the Scheme of Amalgamation and Merger of Sun Pharma Global FZE with Sun Pharmaceutical Industries Limited ("Transferor Company") with Sun Pharmaceutical Industries Limited ("Transferee Company") and their respective members and creditors ("Scheme of Amalgamation and Merger of the Transferee Company") under the provisions of section 230 to 232 read with section 234 and any other applicable provisions of the Companies Act, 2013.

Table with 4 columns: Sr. No, Class of Meetings, Date of Meeting, Time (IST). Rows for Unsecured Creditors and Equity Shareholders.

The equity shareholders and unsecured creditors can attend the respective meetings by logging in at www.evotingindia.com before the commencement of the meetings.

Copies of the respective Notices which include the Scheme of Amalgamation and Exploratory Statement under Section 102 & 230 of the Companies Act, 2013 can be obtained free of charge at the Registered Office of the Transferee Company and/or at the office of the Advocate Mrs. Swati Saurabh Soparkar at 301, Shivali-10, Opp. SBI Zonal Office, S. M. Road, Ambavadi, Ahmedabad 380 015, Gujarat, India.

In view of the meetings being held by VC/ OAVM, and pursuant to order issued by NCLT, the facility to appoint proxy to attend and cast vote on behalf of members and/or unsecured creditors is not available for these meetings.

NCLT has appointed Mr. Gautam Doshi, Chartered Accountant and an Independent Director of the Transferee Company and failing him, Mr. Gaurang Parikh, Independent practicing Chartered Accountant and Partner of Gaurang Parikh, Chartered Accountants, to act as the Chairman of the said meetings including any adjournment(s) thereof.

The Scheme of Amalgamation, if approved in the aforesaid Meetings, will be subject to the subsequent approval of NCLT or any other regulatory authorities.

The equity shareholders of the Transferee Company are hereby informed and requested to note that:

- 1) Since the meeting of the equity shareholders is being held by VC/ OAVM, and therefore, the facility to appoint proxy to vote on behalf of the equity shareholders is not available for this meeting. However, in terms of Section 112 and 113 of the Companies Act, 2013, corporate members are entitled to appoint their authorized representatives to attend and cast vote by electronic means.
2) In compliance with said NCLT Order and the provisions of Section 230(4) and Section 108 of the Companies Act, 2013 and the rules made thereunder and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with MCA Circulars and SEBI Circulars, the Transferee Company is providing the facility of remote e-voting and e-voting during the meeting to the equity shareholders of the Company to cast their votes. The Company has appointed Central Depository Services (India) Limited ("CDSL") as the agency to provide the facility of VC/ OAVM, remote e-voting and e-voting during the meeting.

The remote e-voting period for equity shareholders shall commence on and from Saturday, March 13, 2021 at 9:00 a.m. IST and end on Monday, March 15, 2021 at 5:00 p.m. IST (inclusive of both the days). During the remote e-voting period, equity shareholders of the Transferee Company holding shares either in physical form or in a dematerialised form as on cut-off date may cast their vote through remote e-voting. The remote e-voting module shall be disabled by CDSL for voting thereafter. The facility for e-voting is also available during the Meeting for the equity shareholders attending the Meeting, and who have not cast their vote by remote e-voting. The necessary instructions for attending the meeting, remote e-voting & e-voting during the meeting have been set out in the said Notice dated January 22, 2021.

3) Voting rights shall be reckoned on the paid-up value of the shares registered in the names of equity shareholders as on Tuesday, March 9, 2021. The voting right of equity shareholders shall be in proportion to one vote per fully paid equity share of the Transferee Company held by them.

4) The Transferee Company has completed sending of Notice of NCLT Convened Meeting of the equity shareholders on February 9, 2021 via email to all the equity shareholders whose email address were available with the Transferee Company/Depositories and via physical dispatch to the equity shareholders at their registered address to those equity shareholders who have not registered their email address with the Transferee Company/Depositories and to those equity shareholders whose email address is registered but have opted for a physical copy of the same. Those shareholders who wish to get their e-mail address registered are requested to contact the Company at secreta@sunpharma.com or the Company's Registrar & Transfer Agents, M/S Link Intime (India) Pvt Ltd. at rt.helpe@linkintime.co.in.

5) Any person who becomes a shareholder of the Transferee Company after dispatch of the Notice and holds shares of the Transferee Company as on the cut-off date i.e. March 9, 2021 and whose PAN is not registered with the Transferee Company may obtain the e-voting details by writing to the Transferee Company's Registrar & Transfer Agents, M/S Link Intime (India) Pvt. Ltd. at rt.helpe@linkintime.co.in.

6) Equity shareholders may attend the Meeting even after casting vote through remote e-voting but cannot vote again during the Meeting.

The unsecured creditors of the Transferee Company are hereby informed and requested to note that:

- 1) The voting shall be carried out through e-voting during the Meeting of unsecured creditors.
2) The Company has appointed Central Depository Services (India) Limited ("CDSL") as the agency to provide the facility of VC/ OAVM and e-voting during the meeting.
3) Voting rights shall be in proportion to the outstanding value of the unsecured creditors as per the books of accounts of the Transferee Company as on March 9, 2021.
4) The Transferee Company has completed sending of Notice of NCLT Convened Meeting of the unsecured creditors on February 9, 2021, via email to all the unsecured creditors whose email address were available with the Transferee Company and via physical dispatch to the remaining unsecured creditors at their registered address.
5) Any person who becomes an unsecured creditor after the dispatch of Notice and whose name appears in the books of accounts of the Transferee Company as on March 9, 2021, may write to CDSL or the Company at secreta@sunpharma.com to obtain login credentials for attending and e-voting at the meeting.
6) The necessary instructions for attending the meeting e-voting during the meeting have been set out in the Notice of NCLT Convened Meeting of unsecured creditors dated January 22, 2021.
7) Since the meeting is being held by VC/ OAVM, there is no facility for the unsecured creditors to appoint a proxy. However, unsecured creditors who are corporate bodies may appoint an authorized representative to attend and vote during the meeting.

As directed by NCLT, Mr. Chintan J. Goswami, partner of M/S KJB & Co. LLP, Practising Company Secretary, has been appointed as the Scrutinizer to scrutinize the voting of equity shareholders by remote e-voting and e-voting during their meeting, and voting of unsecured creditors by e-voting during their meeting.

The respective meetings of the equity shareholders and unsecured creditors are being held by VC/ OAVM in compliance with the applicable provisions of the NCLT Order, MCA Circulars and SEBI Circulars.

In case of any grievance connected with remote e-voting and e-voting during the meetings, the equity shareholders and/or unsecured creditors may contact to Mr. Rakesh Dahiya, Manager, CDSL, A Wing, 25th Floor, Marathon Futurex, Mafatal Mills Compound, N. M Joshi Marg, Lower Parel (East), Mumbai - 400 013, Maharashtra, India, email ID: helpe@linkintime.com

Date : February 9, 2021
Place : Mumbai
Chairman appointed for the Meetings

Gautam Doshi
DIN:00004612

Large financial statement table for Tamilnadu Petroproducts Limited with multiple columns and rows of financial data.

ICICI Prudential Asset Management Company Limited
Corporate Identity Number: A511010119

Office: 12th Floor, Narain Manzil, 23, Barakhamba Road, New Delhi 110002
One BKC, 13th Floor, Bandra Kurla Complex, Mumbai - 400050

Notice-cum-Addendum to the Scheme Information Documents (SID) and Key Information Memorandum (KIM) of the schemes ("the Schemes") of ICICI Prudential Mutual Fund ("the Fund")

Pursuant to SEBI circular no. SEBI/HO/IMD/DF3/CIR/P/2020/197 dated October 05, 2020 with respect to Product Labeling in Mutual Fund schemes - Risk-o-meter, investors are requested to take note of the revised Risk-o-meters for the following Schemes of the Fund as mentioned below:

Table with 3 columns: Sr. No., Scheme Name, Risk-o-meter. Rows A-D listing various ICICI Prudential Mutual Fund schemes with their corresponding Risk-o-meter gauges.

The Risk-o-meters are based on evaluation of risk level of the portfolios of the Schemes of the Fund as on January 31, 2021. Risk-o-meters of the Schemes of the Fund not mentioned above remain unchanged from the previous month. The Risk-o-meters of the close-ended scheme(s) of the Fund which have matured as of the date of this Notice cum Addendum, have not been shown.

Investors are requested to take note of the Risk-o-meters while investing through various modes and channels. Further, the Risk-o-meters shall form part of product literature, advertisements and any other communications with respect to the Schemes of the Fund.

All the other provisions of the SIDs and KIMs of the Schemes, except as specifically modified herein above remain unchanged.

This Notice-cum-Addendum forms an integral part of the SIDs and KIMs of the Schemes, as amended from time to time.

For ICICI Prudential Asset Management Company Limited
Place : Mumbai
Date : February 09, 2021
No. 004/02/2021
To know more, call 1800 222 999/1800 200 6666 or visit www.icicprmf.com

As part of the Go Green Initiative, investors are encouraged to register/update their e-mail id and mobile number to support paper-less communications. To increase awareness about Mutual Funds, we regularly conduct Investor Awareness Programs across the country. To know more about it, please visit https://www.icicprmf.com or visit AMFI's website https://www.amfiindia.com

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Registered Office: Barton Centre, Office No. 312/313, Mahatma Gandhi Road, Bangalore 560001, India
Statement of Standalone unaudited Results for the quarter ended on December 31, 2020

Table with 4 columns: Particulars, Quarter ended December 31, 2020, Nine Months ended December 31, 2020, Quarter ended December 31, 2019. Rows include Total income from operations, Loss from Ordinary activities before tax, Reserves, etc.

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For Lerthai Finance Limited
Shao Xing Max Yang
Chairman & Director
DIN 08114973
Place : New Delhi
Date : 9th February, 2021

IIFL ASSET MANAGEMENT logo and detailed financial statement table for IIFL Asset Management with multiple columns and rows.

JM FINANCIAL MUTUAL FUND

JM Financial Mutual Fund notice including Risk-o-meter gauges and text regarding investment and risk.

NOTICE - DIVIDEND DECLARATION

UTI Hybrid Equity Fund (Formerly known as UTI Balanced Fund)
NAV as on 08.02.21 (per unit)

Table with 2 columns: Name of Fund, NAV as on 08.02.21 (per unit). Rows for UTI Hybrid Equity Fund and UTI Hybrid Equity Fund - Dividend Option - Direct Plan.

\*Distribution of above dividend are subject to the availability of distributable surplus as on record date. Dividend payment to the investor will be lower to the extent of statutory levy (if applicable).

Pursuant to payment of dividend, the NAV of the dividend options of the scheme would fall to the extent of payout and statutory levy (if applicable).

Such of the unitholders under the dividend options whose names appear in the register of unitholders as at the close of business hours on the record date fixed for each dividend distribution shall be entitled to receive the dividend so distributed.

Mumbai
February 09, 2021
Toll Free No.: 1800 266 1230
Website: www.utimf.com

The time to invest now is through - UTI SIP
REGISTERED OFFICE: UTI Tower, 'Gn' Block, Bandra Kurla Complex, Bandra (E), Mumbai - 400051.
Phone: 022 - 66786666. UTI Asset Management Company Ltd. (Investment Manager for UTI Mutual Fund)
E-mail: invest@uti.co.in, [CIN-U65991MH2002PLC137867].

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

◆◆◆◆◆◆◆◆◆◆

